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Background: The Burkholderia cepacia complex (BCC) is one of the most important groups of organisms infecting cystic fibrosis (CF)
patients. The aim of the study was to examine how infection with BCC affects clinical outcome. Methods: Nineteen CF adults infected with
BCC and 19 controls infected with Pseudomonas aeruginosa were studied over a 4-year period. The best forced expiratory volume in 1 s
(FEV1) and body mass index (BMI) for each year were recorded and annual rate of decline calculated. Results: The BCC infected group
displayed a significantly greater reduction of FEV1 and BMI compared to the P. aeruginosa infected group ( p = 0.001 and p = 0.009,
respectively). Sixteen patients infected with a single Burkholderia cenocepacia strain had a significantly greater rate of FEV1 decline
compared to those infected with Burkholderia multivorans (n = 3) or P. aeruginosa ( p = 0.01 and p < 0.0001, respectively). The rate of BMI
decline was significantly greater in patients infected with B. cenocepacia compared to those with P. aeruginosa ( p = 0.007), but not
significantly different in those with B. multivorans ( p = 0.29). Conclusion: BCC infection is associated with an accelerated decline in
pulmonary function and BMI. Infection with a single B. cenocepacia strain was associated with a more rapid decline in lung function than
those infected with either B. multivorans or P. aeruginosa.
D 2004 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.Keywords: Cystic fibrosis; Gram negative infection; Clinical outcome
1. Introduction individuals [4] and consequently display increased morbidityBurkholderia cepacia complex is a group of related
species consisting of at least nine members. The organism
was first isolated as a plant pathogen in onions in the late
1940s [1]. However, it was not until the mid 1980s that this
gram negative bacillus was reported as an opportunistic
pathogen in patients with cystic fibrosis (CF) [2,3]. Patients
infected withB. cepacia complex show a significantly greater
decline in pulmonary function compared to non-infected1569-1993/$ - see front matter D 2004 European Cystic Fibrosis Society. Publish
doi:10.1016/j.jcf.2004.01.005
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E-mail address: stuart.elborn@bch.n-i.nhs.uk (J.S. Elborn).and mortality [5,6]. There is strong evidence of patient-to-
patient spread in CF populations both in and outside of
hospital [7,8]. Furthermore, B. cepacia complex infection
can lead to the development of ‘cepacia syndrome’, a rapidly
fatal pneumonia with associated bacteraemia [2]. Treatment
of infection is difficult as B. cepacia complex is inherently
resistant to multiple antibiotics and so the use of antibiotic
combinations as aggressive treatment is increasing [9].
The B. cepacia complex is made up of at least nine taxa,
or genomovars. A genomovar is used to describe a species
that is phylogenetically distinguishable but phenotypically
indistinguishable from another. However, more recently
several phenotypic distinguishing characteristics have been
described for B. cepacia genomovars I, II, IV, V, VII–IX
[10] and B. cepacia genomovar VI [11] which have allowed
these to be formally named with approved binomial names.ed by Elsevier B.V. All rights reserved.
Table 1
Burkholderia cepacia complex: genomovar types and names
Genomovar type Name
Genomovar I B. cepacia
Genomovar II B. multivorans
Genomovar III B. cenocepacia
Genomovar IV B. stabilis
Genomovar V B. vietnamiensis
Genomovar VI B. dolosa
Genomovar VII B. ambifaria
Genomovar VIII B. anthina
Genomovar IX B. pyrrocinia
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Burkholderia cenocepacia and four subgroups have been
identified (A to D) by recA sequence phylogeny and [12]
(Table 1). With further study the number of genomovars
may increase.
It is uncertain whether all genomovar types of B. cepacia
complex that infect CF patients are clinically important. The
aim of this study was to compare the clinical course of CF
patients infected with Burkholderia multivorans (genomo-
var II), B. cenocepacia or Pseudomonas aeruginosa.Table 2
Clinical details of patients in the study groups in 1996 and 2000 mean
(S.D.)
Year B. cenocepacia B. multivorans P. aeruginosa
1996 2000 1996 2000 1996 2000
Number 16 9 3 3 19 19
Sex 12M
4F
5M
4F
0M
3F
0M
3F
10M
9F
10M
9F
Age
(years)
22.8
(4.7)
26
(4.8)
24.7
(7.5)
28.7
(7.5)
22.4
(5.7)
26.4
(5.7)
% FEV1 64.4
(25.3)
61.4
(28.8)
84.8
(11.4)
82.0
(7.4)
72.7
(25.0)
76.1
(24.4)
BMI
(kg/m2)
20.3
(2.3)
20.4
(2.3)
20.9
(0.1)
20.2
(0.5)
21.0
(3.0)
21.4
(3.2)2. Materials and methods
Patients attending the adult CF centre in Belfast from
1996 to 2000, who were chronically infected with B.
cepacia complex, were identified. All B. cepacia complex
infected patients were infected for at least 6 years prior to
the study period. This group of patients was matched for age
(F 3 years) and lung function (F 10% predicted) with a
control group of patients who were chronically infected with
P. aeruginosa. Chronic infection was defined as three or
more positive sputum cultures over a 6-month period.
Sputum culture was performed on a 3-monthly basis
throughout the study.
Organisms of the B. cepacia complex were isolated from
the patients’ sputum by culture on MAST selective agar
(MAST Diagnostics, Liverpool, UK). Isolates were initially
analysed using the API 20NE phenotypic identification
system (BioMe`rieux, Marcy l’Etoile, France). Genomic
DNA was prepared from all B. cepacia complex isolates
as previously described [13] and their genomovar status and
associated transmissibility/virulence markers determined by
a combination of 16S/16S–23S [14], recA-based PCR [15],
B. cepacia epidemic strain marker (BCESM) [16] and cable
pilus molecular markers [17].
All B. cenocepacia isolates (n = 16) were characterised at
the strain level by employing the random amplification of
polymorphic DNA (RAPD) technique, with the BC270
primer (5V-TGC GCG CGG G-3V), in accordance with the
method of Mahenthiralingam et al. [18].
The best forced expiratory volume in 1 s (FEV1) and
body mass index (BMI) were recorded for each year. For
deceased patients, information was obtained from 1996 tothe time of death and the cause of death was noted.
Independent t-tests were used to compare lung function
and BMI between those with B. cepacia complex infection
and those with P. aeruginosa infection at the start of the
study. Further statistical analysis was determined by calcu-
lating the annual rate of change in FEV1 and BMI for each
group using regression analysis. The results were tested for
linearity. Kruskal–Wallis analysis was used to analyse the
results between those infected with B. multivorans, B.
cenocepacia and P. aeruginosa, while unpaired t-tests were
used to compare patients who had died during the study
period and those still alive. Analysis of Variance (of
residuals after removal of subject effects) and post-hoc
multiple comparisons were also performed. The level of
significance was set at probability ( p) less than 5%
( p < 0.05).3. Results
Nineteen adult patients were chronically infected with B.
cepacia complex from 1996 to 2000. Of these patients, 16
were infected with B. cenocepacia (IIIA), while three were
infected with B. multivorans. All B. cenocepacia IIIA
isolates were positive for the molecular markers, BCESM
[16] and the cable pilus [17] as well as showing a typical
Edinburgh–Toronto (ET12) strain PFGE banding profile
[19] within a small collection of isolates chosen randomly.
RAPD analysis of the 16 B. cenocepacia isolates demon-
strated the presence of a single genotype. The group of B.
cepacia complex patients was matched with 19 patients
infected with P. aeruginosa. The mean (S.D.) age, male to
female ratio, FEV1 (% predicted) and BMI of each group in
1996 and 2000 is recorded in Table 2. All patients remained
chronically infected with either B. cepacia complex or P.
aeruginosa throughout the study period. The use of specific
culture media for B. cepacia complex began in 1990 in
Northern Ireland following an index case in 1989 [4]. There
was no strain replacement in those infected with B. cen-
ocepacia.
There was no significant difference in mean (S.D.) FEV1
or BMI at the start of the study between those infected with
 Fig. 2. Comparison of the rate of BMI decline between the study groups. n
B. cenocepacia, E B. multivorans, z P. aeruginosa.
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(F 0.5 kg/m2)] and those with P. aeruginosa infection [262
ml (F 88 ml) and 20.3 kg/m2 (F 0.97 kg/m2)], p = 0.26 and
p = 0.91, respectively.
The data were shown to be linear with FEV1 and BMI
changing steadily with time. The B. cepacia complex
infected cohort displayed a significantly greater reduction
in FEV1 and BMI compared to the P. aeruginosa infected
group ( p= 0.001 and p = 0.009, respectively). Comparison
of the rates of decline of FEV1 between those infected
with B. cenocepacia, B. multivorans and P. aeruginosa
showed an overall significant difference, p = 0.0005. Sub-
sequent post-hoc multiple comparisons showed that the
median (interquartile range) rate of decline of FEV1 (ml/
year) in those infected with B. cenocepacia [ 140 ml/
year ( 280 to  100 ml/year)] was significantly greater
compared to those infected with B. multivorans [6 ml/year
( 110 to 32 ml/year)] or P. aeruginosa infection [ 32
ml/year ( 87 to 21 ml/year)] ( p = 0.01 and p < 0.0001,
respectively) (Fig. 1). The rate of FEV1 decline between
those with B. multivorans and P. aeruginosa was not
significantly different ( p = 0.88).
The overall comparison of the annual rate of BMI decline
between the three groups was significantly different,
p = 0.027. However, post-hoc multiple comparisons showed
no difference in the rate of decline between those infected
with B. multivorans [0.1 kg/m2/year ( 0.05 to 0.25 kg/m2/
year)] and B. cenocepacia [ 0.3 kg/m2/year ( 0.6 to 0.7
kg/m2/year)] or between those with B. multivorans and P.
aeruginosa [0.2 kg/m2/year ( 0.04 to 0.4 kg/m2/year)]
( p = 0.29 and p = 0.77, respectively). However, patients
infected with B. cenocepacia had a significantly greater
annual rate of BMI decline compared to those infected with
P. aeruginosa ( p = 0.007) (Fig. 2).
Further analysis using Univariate Analysis of Variance
(removing subject effects and not imposing a linear effect)
showed a time by group interaction for rate of FEV1 decline
between the three groups, p = 0.004. There was a trendFig. 1. Comparison of the rate of FEV1 decline between the study groups.n
B. cenocepacia, E B. multivorans, z P. aeruginosa.towards a year by group effect for the rate of BMI decline
between the groups, p = 0.38 but this was not statistically
significant.
During the study, seven patients infected with B. cen-
ocepacia died, of which three were due to ‘cepacia syn-
drome’. There were no deaths in the B. multivorans group.
In the total population of patients (n = 50) infected with P.
aeruginosa in 1996 in the CF centre, four (8%) died during
the study period. This was significantly less than the seven
(36.8%) patients infected with B. cepacia complex who died
during the study period (v2 8.6, p = 0.03). The mean (S.E.)
time from the start of the study period to time of death was
3.4 (0.2) years in the B. cepacia group. The mean (S.D.)
rates of decline of FEV1 and BMI during the 2 years prior to
death were significantly greater in the seven patients who
died during the study period [ 286 (F 142.6) ml/year and
 0.5 (F 0.5) kg/m2/year] in comparison to the 12 patients
infected with B. cepacia complex who were still alive
[ 103 (F 89.8) ml/year and  0.03 (F 0.4) kg/m2/year]
( p = 0.003 and 0.04, respectively).4. Discussion
Previous studies have found that CF patients infected
with B. cepacia complex have a greater deterioration in lung
function, require more frequent antibiotic therapy and also
display increased mortality compared to patients with P.
aeruginosa [4,8,20,21]. This study provides further evi-
dence that infection with B. cepacia complex is associated
with an increase in patient morbidity and mortality com-
pared to infection with P. aeruginosa. Most studies have
shown that in pulmonary infection with B. cepacia complex
outcome varies considerably from a rapid fatal decline in
lung function associated with bacteraemia to an acceleration
of pulmonary decline to chronic asymptomatic infection
[2,21,22], suggesting that pathogenicity within the B. cepa-
cia complex varies. Our data further suggests that the
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cepacia complex may also depend on the nature of the sub
species responsible for infection. Within our study popula-
tion, we found that patients chronically infected with a
single strain (IIIA, ET12) of B. cenocepacia displayed a
significantly greater reduction in FEV1 compared to patients
with B. multivorans infection. There is a significant Beta
error present due to the small number of B. multivorans
patients, but interquartile ranges are given to demonstrate
the spread of values. It is not known whether there are any
differences in clinical outcome for the four subgroups of B.
cenocepacia infection.
We could not detect any difference in BMI decline
between the genomovar species. Our data suggests that
the clinical course in patients infected with B. multivorans
maybe comparable to that seen with P. aeruginosa rather
than B. cenocepacia.
These results are consistent with the study of Mahenthir-
alingam et al. [23], who showed that B. cenocepacia was
associated with ‘cepacia syndrome’ and a high mortality in
CF patients compared to those infected with B. multivorans.
Studies have demonstrated a reduction in survival following
pulmonary transplantation in CF patients infected with B.
cepacia complex compared to those either without B.
cepacia complex infection or those with panresistant P.
aeruginosa infection [24,25]. In addition, CF patients un-
dergoing pulmonary transplantation had a worse outcome
when infected with B. cenocepacia prior to surgery in
comparison to patients with pre-transplant B. multivorans
or B.vietnamiensis infections [26].
In regard to the pathogenicity of B. multivorans, a recent
study by Schwab et al. [27] demonstrated that a B. multi-
vorans strain (J-1) was able to penetrate well-differentiated
airway epithelial cell cultures, a phenomenon thought to
result in bacteraemia and ‘cepacia syndrome’. Whiteford et
al. [28] reported deaths associated with an outbreak of B.
cepacia complex in patients in a Glasgow clinic. The strain
responsible for this has subsequently been identified as B.
multivorans [29]. Mahenthiralingam et al. [23] showed that
phylogenetic analysis of the recA gene of the strain of B.
multivorans infecting a Vancouver population was geneti-
cally different from the index B. multivorans strain in the
Glasgow epidemic. So, there is increasing evidence for
various strains of B. multivorans with different pathogenic-
ity and clinical outcomes [20].
It is uncertain if infection with B. cepacia complex is the
cause of a more rapid pulmonary decline in CF patients or if
it is merely a marker of disease severity in those with more
severe underlying disease. Case control studies have shown
that in patients with CF, B. cepacia complex infection is an
independent negative prognostic indicator [20]. Tablan et al.
[6] had closely matched parameters characterising disease
severity yet reported early excess mortality in patients
infected with B. cepacia complex. McCloskey et al. [4]
studied the same patient group as in our study and showed
that there was no difference in pulmonary function betweenpatients at the time of acquisition of B. cepacia complex
compared to P. aeruginosa, but did demonstrate that lung
function declined more rapidly in the B. cepacia complex
group. At the time of the study by McCloskey et al.,
differentiation of genomovars could not be performed so
the B. cepacia complex infected group was studied as a
whole. It has been demonstrated that patients infected with
B. cepacia complex had a higher frequency of intravenous
antibiotic therapy and higher long-term mortality when
compared to patients without B. cepacia complex infection
[22].
Not only is there clinical variation between patients
infected with B. cenocepacia, B. multivorans and P. aeru-
ginosa but there may be a subgroup of those infected with
B. cenocepacia with a worse prognosis. During this study, 7
out of 16 patients infected with B. cenocepacia (IIIA, ET12)
died. This subgroup of patients displayed accelerated rates
of FEV1 and BMI decline when compared to those still
alive, confirming that spirometry and nutritional status are
important prognostic indicators of survival. In 50% of
patients who died, the cause of death was ‘cepacia syn-
drome’. Our results demonstrate considerable variation in
clinical outcome for patients infected with B. cenocepacia
(IIIA, ET12). It is not clearly understood why certain
patients with B. cenocepacia infection display a general
decline in lung function, while other patients develop
‘cepacia syndrome’. Differences in virulence may be a
possible explanation for individuals infected with distinct
strains. Organisms of the B. cepacia complex produce a
variety of classical virulence determinants including pro-
teases, haemolysins, lipase and endotoxin [30]. The cable
pilus gene [31] and BCESM [16] are transmissibility
markers that have been identified that may increase viru-
lence among certain strain types. Cable pili are expressed by
the infamous ET12 strain (one of the ‘hypertransmissible’ or
‘epidemic’ strains) [32], while BCESM has been identified
in several epidemic stains of B. cepacia complex but is not
present in non-epidemic strains [16].
There is potential for significant variation in the genetic
content between strains due to the large genome size of B.
cepacia complex bacteria (2–4 replicons) which may alter
virulence [33]. But patients infected with the same strain can
display considerable variation in clinical outcome, indicat-
ing that the host response may also be important. Mannose-
binding lectin (MBL) is essential in innate immunity,
especially in protecting against bacterial and viral infections
during infancy, before the adaptive immune system is
established [34]. Garred et al. [34] demonstrated that B.
cepacia complex infection was significantly more frequent
in carriers of MBL-variant alleles than in homozygotes.
Prevention of B. cepacia complex infection may be the
most important clinical issue due to the high level of
resistance to antimicrobial drugs and the increase in mor-
bidity and mortality associated with infection. The most
effective strategy to date has been segregation of patients
based on the presence or absence of infection. In the Adult
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cenocepacia from those with other B. cepacia genomovar
infections, such as B. multivorans. Recent studies have
found that virulent and transmissible strains of B. cenoce-
pacia can replace other genomovar infections, such as B.
multivorans [23], so segregation is extremely important. In
our unit, there have been two new cases of B. cepacia
complex infection within the past 7 years since adopting this
policy.
In addition to the segregation policies, it is vitally
important to carry out frequent sputum cultures to detect
B. cepacia complex infection as early as possible and hence
reduce the risk of cross infection. Reliable sputum culture
and unequivocal identification of B. cepacia complex does
require experience and expertise. Due to their complex
taxonomy, confirmation that isolates are organisms of the
B. cepacia complex can be problematic when using com-
mercially available phenotypic identification kits [35,36].
As such methods do not allow genomovar differentiation, a
significant number of PCR-based methods have been de-
scribed to aid laboratory diagnosis of B. cepacia complex
isolates. Furthermore, molecular-based tests have also been
applied directly to CF sputum in an attempt to facilitate
rapid as well as early detection and identification of these
pathogens [14].
The power of this study is limited by the size of our B.
multivorans population, with one patient having insufficient
data for BMI analysis. Further studies involving larger
numbers of patients need to be conducted in order to
confirm these findings. Despite these limitations, a number
of conclusions can be drawn. Genomovar status appears to
be clinically important. Although an association has previ-
ously been demonstrated between infection with B. cepacia
complex and an accelerated decline in pulmonary function,
this data suggests a more rapid decline in lung function in
patients infected with B. cenocepacia (IIIA, ET12) com-
pared to those infected with B. multivorans or P. aerugi-
nosa. These findings emphasise the importance of
genomovar identification methods becoming integrated into
routine diagnostic laboratories and the necessity for strict
infection control policies.References
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